论文部分内容阅读
目的探讨阿德福韦酯联合拉米夫定治疗慢性乙型肝炎的临床疗效。方法收集我院收治的54例慢性乙型肝炎患者资料,将患者随机分为治疗组(给予拉米夫定治疗)和对照组(给予拉米夫定联合阿德福韦酯治疗),均为27例,比较两组患者的临床治疗效果。结果对两组患者治疗后丙氨酸转氨酶(ALT)复常率、乙肝病毒变异株蛋白(YMDD)异常率、乙肝病毒脱氧核糖核酸(HBV-DNA)转阴率和乙型肝炎e抗原(HBe Ag)转阴率进行比较,治疗组患者各指标均优于对照组,差异有统计学意义(P<0.05)。结论阿德福韦酯联合拉米夫定治疗慢性乙型肝炎临床疗效较为理想。
Objective To investigate the clinical efficacy of adefovir dipivoxil combined with lamivudine in the treatment of chronic hepatitis B. Methods The data of 54 patients with chronic hepatitis B admitted to our hospital were collected and randomly divided into treatment group (given lamivudine treatment) and control group (given lamivudine plus adefovir dipivoxil treatment), all of which were 27 cases, the clinical efficacy of the two groups were compared. Results After treatment, the abnormalities of alanine aminotransferase (ALT), abnormality of YMDD, HBV-DNA negative rate and hepatitis B e antigen (HBe Ag), the indexes in the treatment group were better than those in the control group, the difference was statistically significant (P <0.05). Conclusion Adefovir dipivoxil combined with lamivudine treatment of chronic hepatitis B clinical efficacy is ideal.